BIOTRICITY INC.
For the period ended Mar 31, 2025. Filed Jul 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jul 15, 2025
BTCY$0.14+7.5%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| As at March 31, 2025 | As at March 31, 2024 | |
|---|---|---|
| $ | $ | |
| CURRENT ASSETS | ||
| Cash | 365,145 | 786,060 |
| Accounts receivable, net | 1,658,772 | 1,468,655 |
| Inventory [Note 3] | 1,555,385 | 1,879,402 |
| Deposits and other receivables | 1,059,990 | 336,456 |
| Total current assets | 4,639,292 | 4,470,573 |
| Deposits and other receivables [Note 12] | 109,297 | 85,000 |
| Long-term accounts receivable | 70,713 | 149,907 |
| Property and equipment [Note 13] | 9,599 | 15,552 |
| Operating right of use assets [Note 12] | 812,053 | 1,221,593 |
| TOTAL ASSETS | 5,640,954 | 5,942,625 |
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities [Note 4] | 7,661,924 | 9,613,118 |
| Convertible promissory notes and short term loans [Note 5] | 9,618,738 | 9,236,471 |
| Term loan, current | 2,400,000 | 2,400,000 |
| Derivative liabilities [Note 8] | 424,200 | 991,866 |
| Operating lease obligations, current [Note 10] | 531,286 | 457,371 |
| Total current liabilities | 20,636,148 | 22,698,826 |
| Federally guaranteed loans [Note 7] | 870,800 | 870,800 |
| Term loan [Note 6] | 12,271,559 | 9,985,033 |
| Derivative liabilities [Note 8] | 1,478,717 | 1,435,668 |
| Operating lease obligations | 397,830 | 929,115 |
| TOTAL LIABILITIES | 35,655,054 | 35,919,442 |
| MEZZANINE EQUITY | ||
| Series B Convertible Redeemable preferred stock, 0.001 par value, 600 shares authorized as of March 31, 2025 and March 31, 2024, respectively, 385and 265 shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively [Note 9] | 2,000,290 | 1,488,920 |
| STOCKHOLDERS’ DEFICIENCY | ||
| Preferred stock, $0.001 par value, 9,979,400 shares authorized as of March 31, 2025 and March 31, 2024, respectively, 1 share issued and outstanding as of March 31, 2025 and March 31, 2024 [Note 9] | 1 | 1 |
| Preferred stock, $0.001 par value, 20,000 authorized as at March 31, 2025 and March 31, 2024, respectively, 200 and 6,304 preferred shares issued and outstanding as at March 31, 2025 and as at March 31, 2024, respectively [Note 9] | - | 6 |
| Common stock, $0.001 par value, 125,000,000 authorized as at March 31, 2025 and March 31, 2024, respectively. Issued and outstanding common shares: 26,081,295 and 9,353,768 as at March 31, 2025 and March 31, 2024, respectively, and exchangeable shares of 160,672 outstanding as at March 31, 2025 and March 31, 2024, respectively [Note 9] | 26,243 | 9,515 |
| Shares to be issued (581,599 and 324,276 shares of common stock as at March 31, 2025 and March 31, 2024, respectively) [Note 9] | 284,244 | 269,065 |
| Additional paid-in-capital | 106,971,115 | 95,723,083 |
| Accumulated other comprehensive gain (loss) | 145,792 | 32,378 |
| Accumulated deficit | (139,441,785) | (127,499,785) |
| Total stockholders’ deficiency | (32,014,390) | (31,465,737) |
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIENCY | 5,640,954 | 5,942,625 |
Commitments and contingencies*[Note 11]*
Subsequent events*[Note 14]*
See accompanying notes to consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.